Category: Cancer Therapy

Dr. Mikhail Blagosklonny and His Vigilant Fight Against Ageing

Dr. Blagosklonny has been interested in the world of medicine from a very young age, explaining why he acquired both his M.D. in Internal Medicine and Ph.D. in experimental medicine and cardiology from the First Pavlov State Medical University Of St. Petersburg. His performance was so exemplary to the point that he qualified for a job at New York Medical College in Valhalla as an associate professor in 2002.Once he was done with that, Dr. Blagosklonny went on to challenge himself with a position in Ordway Research Institute as a Senior Scientist right before ending up at Roswell Park Cancer Institute as an Oncology Professor in 2009. That was when his research in rapamycin intensified and made enormous progress.Dr. Blagosklonny has been in the business of making sure that he finds much better and less invasive ways of treating cancer. He ensured that he was always in a position to get work done by developing an anti aging drug called rapamycin, one that he later wrote a paper on about how it can be utilized properly.

Dr. Blagosklonny wrote that the use of rapamycin would go a long way in slowing the aging rate as it targets particular cells that trigger the latter hence making the entire process slower. In layman terms, the medication has some rather straightforward modus operandi which acts on the principle of protecting healthy cells from damage as the cancer cells are attacked.The use of rapamycin, Dr. Blagosklonny stated, will most likely affect the TOR signaling in aging and cancer, which can without a doubt boost the lifespan of the consumer. He attributed old age to cells being damaged, and since our bodies to rejuvenate them as fast as possible, they die off at a much faster rate than normal which is the cause of aging.When healthy cells are protected, then the body functions will always work which will result in a boost in the immune system. And since he had spent a couple of years studying bio gerontology (which is the science of studying the underlying body mechanisms that result to aging).

Dr. Blagosklonny has been able to consider the kind of effects that patients who consume rapamycin are having, both in the short and long term.Apart from being an adroit researcher and scientist, Dr. Blagosklonny is also known for his impressive writing as reflected in quite some publications that sparked a worldwide interest once published. Some of his publications include Cancer Biology & Therapy where he was both a contributor and editor.In total, the brilliant oncology specialist has written close to 270 pages in total, making sure that he shares his knowledge with millions of people around the globe. The latter has resulted to his effective outsourcing over 25,000 citations over the years.Others include Aging, where he was the editor in chief as well as Oncotarget. He also was the editor in chief in Cell Cycle after he carried out an in-depth research on the subject matter. In all the above publications, all of which Dr. Blagosklonny (@Mikhail Blagosklonny) is responsible for making happen, he always made sure that he recommends the use of rapamycin.

How Eric Lefkofsky’s Company is Changing the War on Cancer

Four in 10 Americans are expected to develop cancer at some point in their lives. Fortunately, much progress has been made in the diagnosis and treatment of this dreaded disease, and many of the advances in this area are attributable to the work done by such companies as Tempus. This Chicago-based firm has developed a method that can improve cancer treatment through the principle of human genome sequencing.

Although many types of cancer treatment are available today, the effectiveness of any one method often comes down to understanding the specific needs of the person receiving treatment. Tempus has satisfied these needs by developing a platform that can analyze the clinical and molecular composition of individual patients. The result is a major transformation in the way medical health care delivered.

Eric Lefkofsky, who helped establish Tempus, faced a personal crisis when his wife Liz was diagnosed with breast cancer. It was then that he also learned of the inadequacies in the manner that cancer data was being collected and stored. This problem was overcome by the software that would be developed by his company. Possessing language and character recognition capabilities, this software enabled the faster processing of patient information that is often recorded by hand. Notes could thus be transformed into structured data that could be used in the treatment process.

The work by Tempus will help shift treatment strategies to techniques targeting molecules and cells. The end result will be the development of specific treatments that can be more effective and less costly. Such personalized methods may eventually extend from cancer to the treatment of other diseases.

Although he has been long associated with Chicago, Eric Lefkofsky was born in Detroit. A graduate of the University of Michigan Law School, he would later teach at Kellstadt Graduate School of Business, a division of DePaul University, and at the Kellogg School of Business, which is part of Northwestern University. He is currently adjunct professor at the Booth School of Business division of the University of Chicago.

In addition to his academic service, the 47-year-old entrepreneur serves on the boards of some notable organizations, including the Ann and Robert H. Lurie Children’s Memorial Hospital and the Art Institute of Chicago.

About Eric Lefkofsky: lefkofskyfoundation.com/about-eric-lefkofsky/

Eric Lefkofsky at his Best at Tempus

Eric Lefkofsky is the main founder of Tempus whereby the organization main agenda is to provide information to doctors from the University of Chicago that consist the improvement of treating breast cancer. Tempus are certain they will diagnose data for over 1000 patients who have breast cancer hence the doctors are able to know and handle on how to find ways that will display the response of the breast cancer patients. The company also ensures they improve their data tactics so they can help more people. Together Tempus and other physicians are certain of achieving better ways so they can treat a lot of breast cancer patient.

Some of the specialists who works together with the company is Dr. Olufunmilayo Olopade who is a professor of human genetics and medicine. He is delighted to work with the company in discovering better treatment of cancer patients. Furthermore, he also helps the organization to accomplish the biggest data treatment in breast cancer so they can help more people. Tempus also deal with genomic numbering and machine learning whereby their main objective is to assist doctors in knowing the best cure and time.

Eric Lefkofsky as the CEO of Tempus he is able to manage the organization and also improve the organization system so they can fight cancer and transform people lives. He as well is the founding partner of Lightbank whereby the company deals with technology investment. In addition, he also is the co-founder and chairman of Groupon and as well the founding partner of Uptake Technologies. He studied at the University of Michigan and also he got Juris Doctor from the University of Michigan Law School.Eric Lefkofsky and his wife Liz also participate in charity work together. In the year 2006, they started the Lefkofsky Family Foundation whereby their main aim of the organization is to help and transform people lives in the society through providing them with better creativity so they can develop their businesses. One of other charitable organization where he participates is Lurie Children’s Hospital he acts as the Trustees. He as well consumes his time to lecturing at the University of Chicago.

Cancer Treatment Centers of America Rollout New Treatment Platform

The Cancer Treatment Centers of America are a collection of five hospitals across the nation who all have a common goal: healing and helping those with cancer. Striving to provide the best treatment options to it’s patients, the CTCA combines top-of-the-line care including genomic testing, precision treatment, surgery, radiation and chemo with supportive therapies aimed at helping patients live comfortable lives.

As stated in the article, “Cancer Treatment Centers of America® Partners with Allscripts and NantHealth to Launch Clinical Pathways, a Comprehensive and Custom Oncology Treatment Platform,” though centered in Boca Raton, Florida, the CTCA spans the entire nation from Pennsylvania to Arizona, and includes five hospitals, all with the same goal: fighting cancer and helping patients get better. Each different hospital included in the CTCA network is staffed by experts who aim to provide patients with personalized care meant to fit their needs.

This passion for helping each individual patient with personalized care has brought about some changes for the https://www.myctca.com/(Cancer Treatment Centers of America), who, through their partnership with AllScripts and NantHealth, have launched a program called Clinical Pathways, a comprehensive oncology platform that provides cancer patients with personalized care. This new platform helps the treatment process by informing doctors without interrupting the workflow of the physician, allowing them to treat patients quickly and efficiently, while still remaining on a personal, case-by-case level. This system was designed with oncologists nationwide participating in it’s creation, and aims to offer the most comprehensive and up-to-date information on the disease.

According to Wikipedia, Clinical Pathways aims to present all options that fit the patients needs, as well as helping to prevent guesswork from doctors who are barraged with new treatments, research and data. With this system, it’s easy to see that the CTCA had patients in mind with the creation of this platform, allowing them to choose their own treatment and therapy options from a list deemed safe and helpful to them, ushering in a new dawn of cancer treatment.

Jump to top

Clay Sieagall Explores Quest to Reinvent Cancer Therapy

The field of cancer has seen hundreds of companies venture into research to find better ways of dealing with the menace. One of the most successful companies in this space is Seattle Genetics, which has been delivering cancer treatment solutions using modern and unique technology. As their CEO, Clay Siegall, cited during an interview with Endgadget, the company is looking to reinvent the way people receive cancer therapy and in less than five years, they will have a system that seamlessly deals with the many cancer problems people face. Over the past five years, the stock prices of Seattle Genetics tripled and the company is on an upward growth trajectory.

Clay Siegall has shown great passion and dedication in confronting the fight against cancer. He foresees a world where the lives of cancer patients will be improved through specialized care that can detect and completely eliminate the menace. As the CEO and President of Seattle Genetics, Clay Siegall has been inviting professionals from various companies to join in the research projects that are sponsored by Seattle Genetics. This partnership is meant to bring about a reinvention in the cancer research program that should lead to the development of reliable solutions for cancer patients.

With several drug pipelines, Seattle Genetics has also managed to enter into partnerships with some of the most established companies like GlaxoSmithKline. These partnerships have been a great asset to availing expert support and tools for cancer research projects and the success rate of these projects has been impressive all along.

About Clay B. Siegall, Ph.D.

Clay B. Siegall, a co-founder of Seattle Genetics, is the company’s CEO and President and he also chairs the Board. He is a clinical scientist by profession and when they founded the company in 1998, his ideas were to create a platform inspired by research and innovation. He has been guiding the research projects of the company and he is always careful about quality and offering useful products that support the delivery of strong and reliable solutions. Under his leadership, the company entered into several licenses for the ADC Technology they pioneered.Cancer Therapy